(MENAFN- Investor Brand Network)
Aditxt (NASDAQ: ADTX)
announced a virtual fireside chat on Oct. 28, 2024, featuring Aditxt CEO Amro Albanna and Evofem Biosciences CEO Saundra Pelletier, moderated by Dr. Drew Pinsky. The discussion will provide updates on Aditxt's Acquisition of Evofem, post-acquisition strategies, and the companies' plans to enhance women's health care solutions. Key topics include Evofem's FDA-approved contraceptive gel Phexxi®, the upcoming U.S. re-launch of Solosec®, and the future launch of the Mitomic Endometriosis Test (METTM). The session will explore how Aditxt's platform supports Evofem's growth as a multi-product women's health franchise.
To view the full press release, visit
About Aditxt Inc.
Aditxt is an innovation platform dedicated to accelerating promising health innovations. Aditxt's ecosystem of research institutions, industry partners and shareholders collaboratively drives its mission to“Make Promising Innovations Possible Together.” The innovation platform is the cornerstone of Aditxt's strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder's voice is heard and valued, and empowers collective progress. Aditxt currently operates two programs focused on immune health and precision health. The company plans to introduce two additional programs dedicated to public health and women's health. For these, Aditxt has entered into an arrangement agreement with
Appili Therapeutics Inc. (TSX: APLI) (OTC: APLIF) , which focuses on infectious diseases, and a merger agreement with Evofem. Each program will be designed to function autonomously while collectively advancing Aditxt's mission of discovering, developing and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of the transactions with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing. No assurance can be given that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close. For more information, please visit
.
NOTE TO INVESTORS:
The latest news and updates relating to ADTX are available in the company's newsroom at
About InvestorWire
InvestorWire
(“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within
the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published:
/Disclaimer
InvestorWire
Los Angeles, CA
310.299.1717 Office
[email protected]
InvestorWire is powered by
IBN
MENAFN21102024000224011066ID1108803389
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.